Shamrock Industrial Co Ltd
Shamrock Industrial Co. Ltd. engages in the manufacturing of bulk pharmaceutical, and chemical products. The company is headquartered in Mumbai, Maharashtra. The firm offers a range of manufacturing of pharmaceuticals and drugs products, and allied business activities. The firm's division include Bulk, Pharmaceuticals and Chemicals Division (BPC), Medivet, Research and Development, ERP, Nviro Chemstock and Nutrasciences. BPC comprises of manufacturing and contract manufacturing of active pharmaceutical ingredients (APIs), advance intermediates, intermediates and fine chemicals. The company consists of manufacturing, contract manufacturing and outsourcing products. Medivet division's product range comprise of potent and healthy anthelmintic range. Nviro Chemstock is engaged in exports contract manufacturing API, Intermediates and fine chemicals. The firm's customer portfolio consists of generic API producers, multinational companies, finished formulations manufacturers, and distributers.
Price Trend & Technical Volume
Daily QuotesPrice Chart (Historical Trend)
Interactive index-style Recharts with entry animations
4V Matrix
Multi-dimensional proprietary scoreValuation Comparison
Intrinsic & Fair Value Multiples* DCF valuation criteria: 2-Stage model: 10% growth rate years 1-5, 10.5% discount rate, 3% terminal growth rate
Community Sentiment
Be the first to voteWhat is your outlook on Shamrock Industrial Co Ltd? Anonymous community voting — click an option to cast or update your vote.
AI Diagnostics Score
Weighted model combining fundamental, technical & growth factors.
- Debt/Equity is within safe range (—).
- Piotroski financial solvency score: 5/9.
- Momentum metrics indicate consolidation near key averages.
Historical Returns
Growth Analysis
| Metric | 1-Yr YoY | 3-Yr CAGR | 5-Yr CAGR |
|---|---|---|---|
| Sales | — | — | — |
| Profit | — | — | — |
Institutional Valuation Models & Fundamental Quality Methodology
DesiStocks synthesizes classical institutional valuation models and financial distress frameworks to provide a balanced, multi-dimensional view of Indian equity fundamentals. Review each methodology below to understand its core drivers, appropriate use cases, and inherent assumptions.
Projects operating cash flows minus capital expenditures over a 5-year forecast window, discounted back to present value using the Weighted Average Cost of Capital (WACC). Terminal value assumes a sustainable 4% perpetual growth rate matching India's long-term GDP expansion.
Rooted in classic value investing doctrine: √(22.5 × EPS × Book Value). Graham's formula sets a defensive price ceiling to ensure an investor never pays more than 15x earnings and 1.5x tangible book value simultaneously.
Anchored in Growth at a Reasonable Price (GARP). Equates a fair P/E multiple directly to the sustainable earnings growth rate percentage: Fair Price = EPS × Growth Rate. A PEG below 1.0 signifies potential undervaluation relative to growth.
Nine binary financial tests across profitability (positive ROA, cash flow > net income), balance sheet leverage (declining debt, rising liquidity, zero share dilution), and operational efficiency (improving gross margin and asset turnover). High scores (8–9) confirm robust quality.
Five weighted financial ratios assessing working capital, cumulative profitability, operating leverage, market capitalization, and asset turnover. Proven predictor of balance sheet stress and corporate bankruptcy probability over a 24-month horizon.
Proprietary four-pillar diagnostic framework examining Valuation (multiples vs 5Y history), Value Creation (ROCE spread over WACC cost of capital), Volatility (drawdown containment & beta), and Velocity (operating profit momentum).
All intrinsic valuations and scores are mathematical models generated using publicly available financial statements and historical market disclosures. These calculations do not represent guaranteed future price targets, investment advice, or research analyst buy/sell ratings under SEBI (Research Analysts) Regulations. Always perform independent diligence and consult a licensed financial advisor.